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X-irradiation of eyelid cancers occasionally
results in the complication of leukoplakia of
the palpebral conjunctiva (1). Clinically, such
lesions present as white, adherent plaques in a
site which received incidental radiation dur-
ing the treatment of basal cell epitheliomas
situated on eyelids (Fig. 1). Histologically,
the principal epithelial changes in these
plaques are acanthosis and hyperkeratosis. It
was reasoned that this complication was a
result of irradiation of the palpebral tissues
during the treatment and that the absorbed
radiation dose was due not only to the pri-
mary beam but also to radiation scattered
backward from the all-lead eye shield used to
protect the ocular globe. Scattered radiation is
of lower energy and, thus, more readily ab-
sorbed by the eyelid tissues. To reduce this
scattered radiation, a new multi-layered eye-
shield consisting of a lead core coated with
copper, aluminum and paraffin was constructed
(1).
A further concern in the treatment of eyelid
cancers is the dose of radiation absorbed by
the ocular lens since it is known that X-rays
are cataractogenic in man (2, 3).
In order to determine whether this new eye-
shield accomplishes its purpose of reducing
the amount of radiation received by the eye-
lid and lens, we turned to a recently devised
rod-shaped thermoluminescence dosimeter be-
cause of its small size (1 mm diameter x 6 mm
length). This permits positioning of the do-
simeter in various sites about the eyeshield
and in the anterior chamber of the eye, thns
allowing direct measurements of the dose of X-
radiation which reaches the eyelids and ocular
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lens during radiation therapy for eyelid can-
cers.
THEaMOLUMINE5cENcE DOsIMETRY
Certain crystalline solids, such as lithium
fluoride', have the property of storing radia-
tion energy by a process involving ionization
and trapping of electrons at defects or im-
purities in the crystal lattice. Later, upon
stimulation by heat, the trapped electrons are
released and return to the ground state, the
stored energy being released as light. The
quantity of light emitted can be measured
and related to the dose of radiation received
by the thermoluminescent substance. A detailed
explanation of the luminescence phenomenon
involved is discussed by Sehulman (4).
Lithium flouride (LiF) is a convenient
substance for X-radiation dosimetry in med-
ical and biological research because of several
properties: 1) The absorption of X-radiation
per gram of LiF is nearly equivalent to that
of tissue for many different X-ray energies in
the therapeutic range; 2) its energy storage
is stable over several months; 3) the lumi-
nescence is in the visible spectrum and thus
easily measurable with existing photomulti-
plier tubes; 4) its light output is propor-
tional to dose up to about 5000R and with
calibration curves the usable range extends to
a million roentgens; 5) its response is inde-
pendent of dose rate; and, 6) it is chemically
inert and non-toxic. The characteristics of
light output from LiF as a function of heat-
ing temperature and its integrated dose re-
sponse have been discussed by Cameron et al.
(5) while the dose-rate independence has been
shown by Karzmark et al. (6).
For the measurement of X-radiation dose in
ocular tissues, it is essential to use tiny, tis-
sue-equivalent dosimeters. Lithium fluoride
powder is available in a matrix of Teflon
'The lithium fluoride used in our studies is
Con-Rad type 7: enriched in Li' to 99.993% (sup-
plied by Controls for Radiation, Inc.).
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(polytetrafluoroethylene), an inert plastic of
near tissue-equivalence for X-radiation. Teflon
also has the necessary qualities of high heat
resistance, adequate transmission of light,
and lack of toxicity. The dosimeters used
were LiF-Teflon cylindrical micro-rods (Fig.
2), 1 mm in diameter and 6 mm in length,
obtained from Controls for Radiation, Joe.,
Cambridge, Massachusetts. Each rod weighs
only 10 mg and contains approximately 0.8 mg
of LiF powder. In order to ensure zero initial
energy storage and reproducible sensitivity,
the dosimeters were given the annealing treat-
ment recommended for moderate doses. Thus,
prior to use, the rods were heated to 300° C.
for 15 minutes and then to 80° C. for 2 hours.
The characteristics of LiF-Teflon dosimeters,
their correct handling, and some applications
are discussed further by Bjarngard et al. (7).
The readout system employed was the Mark
Fro. 1. Clinical aspect of post-irradiation leukoplakia of the palpcbral conjunetiva
FIG. 2. Photomicrograph of LiF-Teflon rod placed on illuminated grid. Each division is 1
millimeter.
-s.t S
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Fic. 3. Diagramatic representation of dimen-
sions of eyeshield (above) and cross section of
"new" multilayered eyeshield (below) devised to
reduce scattered X-radiation.
IV TLD reader (Model 1100) obtained from
Radiation Detection Co., Mountain View,
California. This instrument provides a light-
tight housing for the dosimeter, a heating ele-
ment and a photomultiplier tube. The do-
simeter is placed on the heating element which
has a linear heating rate. The anode current
from the photomultiplier tube is amplified
and then integrated by charging a condenser
the voltage of which may be read on a meter.
Each dosimeter was heated to approximately
250° C. in 25 seconds to obtain the lumines-
cence. A subsequent heating gave negligible
luminescence indicating that the first heating
was sufficient to release virtually all the trapped
energy that can be measured by thermolumi-
nescence.
Translation into roentgens of the lumines-
cence measured is achieved by reading out, at
the same time as the experimental dosimeters,
several "standard" dosimeters which had been
exposed in air to known doses of the same
X-radiation beam. Exposure of these "stand-
ard" LiF micro-rods was conducted in the
identical manner as exposure at the same site
of a Siemens air-filled ionization chamber
designed for monitoring X-ray beams of this
energy. Hence, the thermoluminescence was
calibrated in roentgens (air exposure units).
Since the LiF dosimeter materials interact
with X-radiation similar]y to tissue, the ab-
sorbed dose in tissue (rads) may be calcu-
lated using the known conversion factor of
rads per roentgen. For X-radiation with a
half value layer of 0.9 mm of aluminum as
used in these experiments, the corresponding
effective photon energy is approximately 22
key, for which the conversion to soft tissue
dose is 0.92 rads per roentgen (8).
The overall precision of this method for
the smallest doses reported in this study is
estimated as 10% and for doses exceeding
100 rads is This spread is due to the
combined effects of the minute amount of LiF
in the dosimeter rods, variations in readout
efficiency, and background readings which
constitute a significant correction when meas-
uring small doses. However, these uncertainties
do not significantly affect the conclusions
drawn from the measurements given below.
METHOD
The amount of radiation received by the pal-
pebral conjunctiva, the bulbar conjunctiva and
the lens was measured in the following manner.
Orbital contents and a wide zone of periocular
tissues including the eyebrow, eyelids, canthi, and
skin from the lateral aspect of the nose, the upper
malar area and temple were obtained as a single
post-mortem specimen. These tissues were then
placed in anatomic position in the orbital socket
of a human skull. This model was "treated" in a
standardized fashion for a mock eyelid cancer (5
mm in width and 10 mm in length) arbitrarily
placed in the mid-portion of the lower eyelid.
An eyeshield of the dimensions shown in
Figure 3 was inserted into the lower palpebral con-junctival cul-de-sac as illustrated in Figure 4a.
A portal opening measuring 1 cm in width x 2
cm in length was made through a lead sheet of
thickness (0.92 mm) usually used as overlay shield-
ing in treating our patients (see Fig. 4b). This all-
lead overlay shield was used in all the experi-
ments below. A comparison of the doses received
by the palpebral and ocular tissues with the "old"
and "new" eyeshields was then made. The "old"
eyeshield was fashioned from an all-lead sheet
0.92 mm in thickness. The "new" (multilayered)
eyeshield was of similar shape but had a central
core of lead 0.92 mm in thickness electroplated
with 025 mm copper, and coated with 0.5 mm
layer of aluminum (Fig. 3). This shield was dipped
into heated paraffin and allowed to cool prior to
insertion into the conjunctival cul-de-sac. The
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Fio. 4. Model used in study. a) The specimen, consisting of human ocular and periocular
tissues, has been placed into a skull. The eyeshield has been inserted into the conjunctival
cul-de-sac. b) Overlay shield with cut out port. Dosimeter (white cylinder) being placed in
position "A" (see figure 5). c) Dosimeter is seen as a small white linear object in the anterior
chamber of the eye (arrow). This is site "C" (see figure 5).
successive coats of the "new" shield serve to ab-
sorb the lower energy radiation scattered from
the inner layers of the shield. The total thickness
of metals in this shield is 2.42 mm which also tends
to reduce the primary-beam radiation reaching the
eye.
The radiation used in these experiments was
generated at 100 kilovolts (peak) at a target-to-
skin distance of 20 cm. The half-value-layer of
this radiation was 0.9 mm of aluminum, which re-
sults from the inherent filtration of our X-ray tube.
A cylindrical X-ray cone 31 mm in diameter was
used to reduce stray radiation.
The thermoluminescence dosimeter rods were
placed in three locations (Fig. 5): A) between
the palpebral conjunctiva and the anterior surface
of the eyesbield, B) between the posterior surface
of the eyeshield and the anterior surface of the
ocular globe and, C) in the anterior chamber of
the eye directly on the surface of the lens (Fig.
4c). Following exposure of this model to X-radia-
tion, the dose received at the three sites was de-
termined by heating the LiF rods and measuring
the emitted light radiation by the photometric
read-out system described above. All experiments
were carried out in duplicate.
RESULTS
Table I summarizes our findings. Using the
"old" (all lead) eyeshield and considering the
air dose at the skin surface as 100%, the aver-
age dose received by the palpebral conjunctiva
was 75% of this dose; by the bulbar conjunc-
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tiva 1.4%; and by the lens 1.2%. Using the
"new" (multilayered) eyeshield, the amount
of radiation received by these structures was
significantly reduced (palpebral conjunetiva
60%; bulbar conjunctiva 1.0%; and lens 0.8%).
Thus, by using the "new" eyeshield the dose
received by the palpebral conjunctiva is re-
duced by 20%; that received by the bulbar
conjunctiva is reduced by 29%; and that re-
ceived by the ocular lens by 33%.
DISCUSSION
FIG. 5. Cross section illustrating sites of place-
ment of thermoluminescence dosimeters. The
heavy black vertical and curved lines indicate po-
sitions of the lead shields. The horizontal lines de-
pict the X-ray beam. The small arrows represent
backscatter radiation emanating from the lead
shield. The sites of placement of the dosimeters
are indicated by the letters A, B and C ("A"—
between palpebral conjunctiva and anterior surface
of the eyeshield; "B"—between posterior surface
of eyeshield and bulbar conjunctsva; "C"—in
anterior chamber of eye resting against the lens).
The X-ray machine used for these studies is
the same one which we use for treating pa-
tients. Based on the results of this study the
total dose received by ocular structures during
our "standard" X-irradiation procedure can
be calculated (Fig. 6). These calculations show
that by using the "new" (multilayered) eye-
shield there is a substantial reduction of the
total dose of X-rays received by these struc-
tures (e.g., the palpcbral conjunctiva receives
510 U less). Thus, the "new" eycshicld designed
to reduce scattered radiation and primary
beam penetration accomplishes its purpose.
Whether the reduction in scattered radiation
is sufficient to circumvent the problem of
TABLE I
Amount of X-radiation received by ocular and eyelid tissues
.Site
Air dose at skin
surface (R)
Old New
shield shield
Dose at site* (R) Surface air dose
j at site (%)
Old New Old New
shield shield shield shield
Average
reduction of
dose by new
shield (%)
A = Palpebral con) unctiva 450
450
450
450
342
333
266
274
76
74
59
61
20
B = Bulbar conjunctiva 4000
4000
4000
4000
52
60
40
40
1.3
1.5
1.0
1.0
29
C = Ocular lens 4000
4000
4000
4000
48
48
36
28
1.2
1.2
0.9
0.7
33
* Doses arc given in roentgens since the LiF thermoluminescence was calibrated using an air-filled
Siemens chamber. The absorbed dose in rads may be obtained by multiplying by 0.92 rads per roentgen.
rii OLD
NEW EVESHIELD
41 21
OCULAR
LENS
FIG. 6. X-ray dose received by eyelid and ocular tissues when our "standard" cancericidal
air dose of 3400 r is used.
post-irradiation conjunctival leukoplakia re-
mains to be seen. Follow-up examinations of
patients treated with tbe "new" eyeshield
should give the answer.
The data also show that the "new" eyeshield
is even more effective than the "old" eyeshield
in protecting the eye itself. With the "new"
eyeshield only 1.0% of the total radiation de-
livered to the skin surface (air dose) reaches
the bulbar eonjunetiva and only 0.8% reaches
the lens. Although the cornea is quite radio-
resistant, the lens is more sensitive to X-
radiation. The amount of radiation necessary
to cause cataract formation in man is not
precisely known. However, the dose is thought
to be in the neighborhood of 500 to 600 roent-
gens with X-rays generated at 100 to 250 kilo-
volts peak (2), although doses as low as 200 R
have been implicated with certain radiation
techniques (3). When using our "standard"
therapy with "new" eyeshield for treatment of
a basal-cell epithelioma of an eyelid, a total
of 3400 roentgens (air dose) is administered.
Of this total, less than 28 roentgens are re-
ceived by the lens, a dose much below that gen-
erally considered to be eataraetogenie in man.
However, since the lens is not a tissue which
rapidly repairs itself, radiation damage to
this structure is probably cumulative through-
out the lifespan of the individual. Thus, any
reasonable means of reducing radiation ex-
posure of the lens is worthwhile.
SUMMARY
A thermoluminescence dosimetry system con-
sisting of lithium fluoride evenly dispersed in
Teflon micro-rods was used to study the dose
of X-radiation received by human ocular and
palpebral tissues during radiation therapy for
eyelid cancers. The advantage of this do-
simetry system is that these small rods can be
strategically placed about the orbital tissues.
X-RAY DOSE RECEIVED BY OCULAR TISSUES 517
3400 3400
4000—
3000—
200 0—
R
0
E
N
T 1000-
G
E
N
S
0
SURFACE AIR
DOSE
PA L PE BR AL
CONJUNCTIVA
40
BULBAR
CONJUNCTIVA
518 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Using an all-lead eyeshield (0.92 mm thick-
ness) and considering the air dose at the eye-
lid skin surface as 100%, the dose of the X-ray
received by the palpebral conjunctiva was
75%; by the bulbar conjunctiva 1.4%; and
by the lens 1.2%. By the use of a newly-con-
structed multilayered eyeshield consisting of a
lead core coated successively with copper,
aluminum and paraffin the amount of X-ra-
diation received by these structures was sub-
stantially reduced (palpebral conjunctival dose
reduced 20%; bulbar conjunctival dose reduced
29%; and lens dose reduced 33%).
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